Zacks Research Weighs in on Esperion Therapeutics, Inc.'s FY2025 Earnings (NASDAQ:ESPR)

Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) - Zacks Research lowered their FY2025 earnings per share (EPS) estimates for shares of Esperion Therapeutics in a research note issued on Monday, April 29th. Zacks Research analyst K. Das now expects that the biopharmaceutical company will post earnings per share of $0.02 for the year, down from their previous forecast of $0.05. The consensus estimate for Esperion Therapeutics' current full-year earnings is ($0.68) per share.

Esperion Therapeutics (NASDAQ:ESPR - Get Free Report) last announced its quarterly earnings data on Tuesday, February 27th. The biopharmaceutical company reported ($0.50) earnings per share for the quarter, beating the consensus estimate of ($0.53) by $0.03. The company had revenue of $32.25 million during the quarter, compared to the consensus estimate of $26.84 million. During the same quarter in the previous year, the business earned ($0.76) EPS.

A number of other equities analysts have also recently commented on ESPR. HC Wainwright reiterated a "buy" rating and set a $16.00 price target on shares of Esperion Therapeutics in a report on Monday, March 25th. Needham & Company LLC restated a "buy" rating and set a $8.00 price objective on shares of Esperion Therapeutics in a research report on Wednesday, April 10th. Finally, Bank of America downgraded shares of Esperion Therapeutics from a "buy" rating to a "neutral" rating in a research report on Wednesday, January 3rd. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. According to MarketBeat, Esperion Therapeutics presently has a consensus rating of "Hold" and a consensus target price of $9.33.

Esperion Therapeutics Stock Performance

Esperion Therapeutics stock traded down $0.02 during midday trading on Tuesday, reaching $1.97. 2,335,626 shares of the company's stock were exchanged, compared to its average volume of 6,609,319. Esperion Therapeutics has a 52 week low of $0.70 and a 52 week high of $3.40. The firm has a market cap of $373.12 million, a price-to-earnings ratio of -0.93 and a beta of 0.84. The stock's 50-day simple moving average is $2.37 and its 200 day simple moving average is $2.02.

Institutional Investors Weigh In On Esperion Therapeutics

Hedge funds have recently bought and sold shares of the stock. Spire Wealth Management raised its position in shares of Esperion Therapeutics by 69.2% in the fourth quarter. Spire Wealth Management now owns 17,767 shares of the biopharmaceutical company's stock valued at $53,000 after buying an additional 7,267 shares in the last quarter. Private Portfolio Partners LLC acquired a new stake in shares of Esperion Therapeutics in the fourth quarter valued at approximately $30,000. Herbst Group LLC acquired a new stake in shares of Esperion Therapeutics in the first quarter valued at approximately $28,000. Summit Financial LLC raised its position in shares of Esperion Therapeutics by 66.8% in the first quarter. Summit Financial LLC now owns 25,864 shares of the biopharmaceutical company's stock valued at $69,000 after buying an additional 10,355 shares in the last quarter. Finally, PSI Advisors LLC raised its position in shares of Esperion Therapeutics by 161.5% in the fourth quarter. PSI Advisors LLC now owns 17,000 shares of the biopharmaceutical company's stock valued at $51,000 after buying an additional 10,500 shares in the last quarter. 47.39% of the stock is currently owned by institutional investors and hedge funds.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.